In short. The criteria are simple and portable: blinded, placebo-controlled, long enough for a visible outcome, and funded independently of the seller.
Key points
- A visible outcome first, because a study that cannot detect the thing claimed has not tested it.
- Then a control group and blinding, because belief changes the answer.
- Then duration, because skin is slow.
A reader does not need to be able to run a trial to grade one. The criteria are short and portable, and applying them takes a few minutes. What follows is the checklist this review uses, given to the reader so the next claim can be graded without help.
Blinded and placebo-controlled
Participants should not know whether they are taking the product or a comparison that looks and tastes the same. This matters more in a supplement than almost anywhere, because the outcomes are subjective and the act of taking something for the skin changes how the skin is described. Without blinding and a control group, a study is measuring the expectation of the people in it as much as the product.
Long enough to matter
Skin changes over months, not days. A study of a few weeks can detect a shift in a reading and cannot detect a visible change, so its duration tells a reader which question it was capable of answering.
Four criteria, in the order that matters
A visible outcome first, because a study that cannot detect the thing claimed has not tested it. Then a control group and blinding, because belief changes the answer. Then duration, because skin is slow. Then independent funding, because the funder chooses the other three. Any study meeting all four would be a genuine change in this subject.
A declared primary outcome
The study should say in advance what it is testing, register that intention, and report the result whether or not it moved. When a trial measures several things and reports the one that changed, the finding is an observation rather than a result, and it cannot be distinguished from chance after the fact.
An outcome a person would notice
The endpoint should be something the participant or a blinded assessor can see: wrinkle severity, laxity, evenness of tone. Or it should be a surrogate whose relationship to a visible outcome has already been established by separate work. Instrument readings in this field do not have that established relationship, so a study resting on them has demonstrated a change in a measurement and nothing about skin.
Independent funding
The final criterion is not about honesty and is about structure. Whoever pays chooses the question, the sample, the duration and the endpoint, and a funder with a product to sell will make those choices in a direction that suits the product. Independent funding does not guarantee a good study, and it removes the predictable lean.
Three ways the criteria get evaded
- Reporting a surrogate reading as though it were the visible outcome the claim names.
- Running the study for weeks and describing the result as though skin had changed.
- Declaring the primary outcome after the results are known, so that whatever moved becomes the finding.
Applied honestly, these criteria do not make every supplement claim false. They make the size of each claim visible, which is what a reader needs in a subject where the marketing is written to be read quickly.
Frequently asked questions
What is the single most important criterion?
A visible outcome. Blinding, controls and duration all matter, but a study that measures only a device reading has not tested the claim, however well it was run. If the claim is about how skin looks, the study has to be able to detect a change in how skin looks, and most of this literature cannot.
Why does independent funding matter so much here?
Because the funder controls the design decisions that determine the answer: the question asked, the sample size, the duration, and which endpoint is primary. A manufacturer funding its own product trial is not doing anything unlawful, and the resulting literature has a predictable direction. Independence is the only structural remedy.
Could a supplement study ever meet these criteria?
There is no reason it could not. None of the criteria is specific to medicines. They are expensive and slow, which is the obstacle rather than a scientific one, and the absence of any such study after this many years and this much commercial activity is itself informative.
Risks & Limitations
- The claim and the evidence are about two different things: a fact about collagen, and a claim about a swallowed product.
- Swallowed collagen is digested into amino acids, and those are the ones ordinary protein already supplies.
- The trials measure hydration and elasticity readings over short periods, and most are funded by the companies selling the product.
- The products are regulated as food, so no approved indication for skin ageing exists and none is required for them to be sold.
- The harm worth naming is delay: a skin change answered with a supplement instead of an assessment.
When to Seek Care
- A mole or patch that is new, changing in size, shape or colour, or not healing — have it assessed by a clinician.
- Skin that is persistently red, painful or broken, or a rash that does not settle — assessed by a clinician.
- A reaction to a supplement, such as a rash, swelling or digestive symptoms that persist, is assessed by a clinician.
- A declared allergy, a condition requiring protein restriction, or a medication interaction makes this an individual clinical question.
References & Further Reading
- World Health Organization (WHO) — ultraviolet radiation and skin cancer prevention guidance
- U.S. Food and Drug Administration (FDA) — dietary supplement regulation and permitted claims
- National Medical Products Administration (NMPA, China) — health food registration and permitted claims
- Cochrane Library — systematic reviews of nutritional supplements for skin
- Chinese Medical Association Dermatology Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.